文献速递眼底病与葡萄膜炎

玻璃体腔注射阿柏西普治疗重度非增殖性糖尿病视网膜病变:PANORAMA随机临床试验结果

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

PANORAMA是一项双盲100周随机临床试验,纳入402只无糖尿病黄斑水肿(DME)且最佳矫正视力≥20/40的DRSS 47或53级眼,比较阿柏西普2q16、2q8/PRN与假注射。阿柏西普组在24、52、100周DRSS≥2步改善比例显著高于对照,且威胁视力并发症和中心型DME发生更少。

要点

  • 阿柏西普24周时58.4%眼DRSS改善≥2步,对照仅6.0%,调整差52.3%。
  • 52周时2q16组65.2%、2q8/PRN组79.9%改善≥2步,对照15.0%。
  • 至100周,阿柏西普组威胁视力并发症和/或中心型DME发生比例显著低于假注射。

核心结论

  • 在无DME的中重度至重度NPDR眼中,阿柏西普治疗在24、52和100周使显著更多眼达到DRSS≥2步改善。
  • 与假注射相比,阿柏西普显著减少威胁视力并发症和中心型DME的发生。
  • 第一年至第二年DRSS结局强调持续VEGF抑制和依从性的必要性。

研究设计与样本

  • PANORAMA为双盲、100周、多中心、随机临床试验(NCT02718326)。
  • 纳入402名成人(每名1眼),DRSS 47或53级、无DME、BCVA≥20/40。
  • 随机分为阿柏西普2q16组135眼、2q8/PRN组134眼、对照组133眼。

主要发现

  • 24周时,阿柏西普合并组269眼中157眼(58.4%)DRSS改善≥2步,对照133眼中8眼(6.0%),调整差52.3%(95%CI 45.2%-59.5%,P<.001)。
  • 52周时,2q16组135眼中88眼(65.2%)改善≥2步(调整差50.1%,95%CI 40.1%-60.1%),2q8/PRN组134眼中107眼(79.9%)(调整差64.8%,95%CI 55.8%-73.9%),对照133眼中20眼(15.0%),P均<.001。
  • 至100周,2q16组135眼中22眼(16.3%)发生威胁视力并发症和/或中心型DME(调整差-34.2%,95%CI -44.6至-23.8),2q8/PRN组134眼中25眼(18.7%)(调整差-31.7%,95%CI -42.5至-20.9),对照133眼中67眼(50.4%),P均<.001。
  • 未发现新的安全性信号。

关键数值与推荐

  • DRSS改善定义为较基线下降≥2步。
  • 阿柏西普2q16方案:初始3次每月注射后间隔8周一次,之后每16周一次。
  • 阿柏西普2q8/PRN方案:初始5次每月注射后每8周一次,第56周起按需给药。

临床怎么用

  • 对于无DME的重度NPDR眼,可考虑阿柏西普治疗以改善DRSS并降低威胁视力并发症和中心型DME风险。
  • 治疗需长期持续VEGF抑制并关注患者依从性,因第二年DRSS结局可能回复。
  • 选择2q16或2q8/PRN方案需结合注射负担与疗效需求个体化决定。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proactive treatment of nonproliferative diabetic retinopathy (NPDR) reduces the risk of progression to vision-threatening complications. OBJECTIVE: To evaluate vascular endothelial growth factor blockade therapy with intravitreal aflibercept injections in eyes with severe NPDR without diabetic macular edema (DME). DESIGN, SETTING, AND PARTICIPANTS: The Study of the Efficacy and Safety of Intravitreal Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (PANORAMA) was a double-masked 100-week randomized clinical trial conducted in multiple centers worldwide. The study included 402 adults with Diabetic Retinopathy Severity Scale (DRSS) level 47 or 53 with no DME and best-corrected visual acuity of 20/40 or better. INTERVENTIONS: Intravitreal injections of aflibercept, 2 mg, every 16 weeks after 3 initial monthly doses and one 8-week interval (aflibercept 2q16 group); intravitreal injections of aflibercept, 2 mg, every 8 weeks after 5 initial monthly doses, with pro re nata (PRN) dosing beginning at week 56 (aflibercept 2q8/PRN group); or sham injections (control group). MAIN OUTCOMES AND MEASURES: Proportions of eyes with a 2-step or greater improvement in DRSS level, vision-threatening complications, and center-involved DME from baseline to weeks 24, 52, and 100. RESULTS: Among 402 participants (1 eye per participant), the mean (SD) age was 55.7 (10.5) years; 225 (56.0%) were male, and 310 (77.1%) were White. A total of 135 were randomized to the aflibercept 2q16 group, 134 to the aflibercept 2q8/PRN group, and 133 to the control group. At 24 weeks, treatment with aflibercept resulted in a 2-step or greater improvement in DRSS level in 157 of 269 eyes (58.4%) in the combined aflibercept groups vs 8 of 133 eyes (6.0%) in the control group (adjusted difference, 52.3%; 95% CI, 45.2%-59.5%; P < .001). At 52 weeks, 88 of 135 eyes (65.2%) in the aflibercept 2q16 group (adjusted difference, 50.1%; 95% CI, 40.1%-60.1%) and 107 of 134 eyes (79.9%) in the aflibercept 2q8/PRN group (adjusted difference, 64.8%; 95% CI, 55.8%-73.9%) compared with 20 of 133 eyes (15.0%) in the control group (P < .001 for both comparisons) showed a 2-step or greater improvement in DRSS level. Fewer eyes treated with aflibercept vs sham injections developed vision-threatening complications and/or center-involved DME through week 100 (22 of 135 eyes [16.3%] in the 2q16 group [adjusted difference, -34.2%; 95% CI, -44.6 to -23.8] and 25 of 134 eyes [18.7%] in the 2q8/PRN group [adjusted difference, -31.7%; 95% CI, -42.5 to -20.9] compared with 67 of 133 eyes [50.4%] in the control group; P < .001 for both comparisons). No new safety signals were identified. CONCLUSIONS AND RELEVANCE: In this study, significantly more eyes with moderately severe to severe NPDR that were treated with aflibercept showed a 2-step or greater improvement in DRSS level at 24, 52, and 100 weeks, and significantly fewer eyes treated with aflibercept vs sham developed vision-threatening complications and center-involved DME. Outcomes on the DRSS between year 1 and 2 emphasize the need for ongoing vascular endothelial growth factor suppression and adherence. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02718326.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Brown DM, Wykoff CC, Boyer D, et al. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 34351414. doi:10.1001/jamaophthalmol.2021.2809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。